Exegenesis Bio's Hong Kong IPO Prospectus Lapses on July 14

According to Zhitong Finance APP, Exegenesis Bio Inc.'s Hong Kong IPO prospectus will lapse on July 14, 2026, six months after its submission on January 14, 2026, with China Bohai Bank International as the sole sponsor. The biopharmaceutical company focuses on gene therapy and oligonucleotide therapeutics.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments